Opdivo (nivolumab)

pCPA File Number: 21745

Negotiation Status:

Concluded with an LOI

Indication(s):

For the adjuvant treatment of completely resected esophageal or gastroesophageal junction cancer in patients who have residual pathologic disease following prior neoadjuvant chemoradiotherapy (CRT)

Sponsor/Manufacturer:

Bristol Myers Squibb Canada Inc.

CADTH Project Number:

PC0253

pCPA Engagement Letter Issued:

2022-06-28

Negotiation Process Concluded:

2022-08-25